BNC Korea Posts Q1 2026 Consolidated Net Loss of 1.3B Won, Declares First Cash Dividend of 70 Won per Share

Consolidated Q1 2026 revenue: 20.7B won (down 18.5% YoY), operating loss 1.5B won, net loss 1.3B won (vs net profit 5.1B won in Q1 2025).
FY2025 year-end cash dividend of 70 won per share (first dividend ever).
Cash and cash equivalents 94.8B won, total borrowings 25B won, debt ratio 18.5% - sound financial structure.
R&D expenses increased to 1.3B won (6.3% of revenue) from 1.0B won in Q1 2025.
Exports account for 64.1% of revenue; aesthetic products segment contributes 64.8%.
Ongoing litigation and criminal case related to Botox (BIENOX) export violation; appeal pending at Supreme Court.
Valuation loss on FVTPL financial assets of 1.9B won recognized.
Subsidiary Korea BTB resolved listing eligibility review; listing maintained.
New investments and license agreements, including 8.02% stake in Leios Therapeutics.